A physiologically based biokinetic (PBBK) model for the alkenylbenzene safrole in humans was developed based on in vitroand in silico-derived kinetic parameters. With the model obtained, the time-and dose-dependent formation of the proximate and ultimate carcinogenic metabolites, 1΄-hydroxysafrole and 1΄-sulfooxysafrole in human liver were estimated and compared with previously predicted levels of these metabolites in rat liver. In addition, Monte Carlo simulations were performed to predict interindividual variation in the formation of these metabolites in the overall population. For the evaluation of the model performance, a comparison was made between the predicted total amount of urinary metabolites of safrole and the reported total levels of metabolites in the urine of humans exposed to safrole, which adequately matched. The model results revealed no dose-dependent shifts in safrole metabolism and no relative increase in bioactivation at dose levels up to 100 mg/kg body weight/day. Species differences were mainly observed in the detoxification pathways of 1΄-hydroxysafrole, with the formation of 1΄-oxosafrole being a main detoxification pathway of 1΄-hydroxysafrole in humans but a minor pathway in rats, and glucuronidation of 1΄-hydroxysafrole being less important in humans than in rats. The formation of 1΄-sulfooxysafrole was predicted to vary 4-to 17-fold in the population (fold difference between the 95th and median, and 95th and 5th percentile, respectively), with the median being three to five times higher in human than in rat liver. Comparison of the PBBK results for safrole with those previously obtained for the related alkenylbenzenes estragole and methyleugenol revealed that differences in 1΄-sulfooxy metabolite formation are limited, being only twofold to fivefold.
Safrole, a natural plant constituent, is the major component of sassafras oil and a minor constituent in star anise, nutmeg, and black pepper. Safrole was documented to be a rodent carcinogen (Borchert et al., 1973; Miller et al., 1983; Wislocki et al., 1977) . The genotoxicity and carcinogenicity of safrole have been related to the formation of DNA adducts (Borchert et al., 1973; Daimon et al., 1998) . Studies on the bioactivation and detoxification of safrole in humans are limited. Chewing of betel quid, which contains Piper betle leaves, containing 15 mg safrole/g fresh weight, has been reported to result in safrole concentrations of up to 420 µM in saliva (Hwang et al., 1992) . A case-control study showed a significant correlation between the incidence of oral squamous cell carcinoma and chewing of betel quid in a Taiwanese population (Ko et al., 1995) . This phenomenon was linked to a high frequency of safrole-DNA adducts in squamous cell carcinoma and oral submucus fibrosis tissues of betel quid users (Chen et al., 1999) .
Safrole and sassafras oil were banned as food additives in 1960 by the U.S. Food and Drug Administration (FDA). In Europe, a limitation of safrole in foodstuff and beverages was set at 1 ppm (The European Council Directive on food flavoring 88/388/EEC, amended by Commission Directive 91/71/EEC) (EEC, 1988) . In 1997, the Committee of Experts on Flavoring Substances (CEFS) of the Council of Europe evaluated safrole and concluded that safrole is a weak hepatocarcinogen in experimental animal studies but also a genotoxic and a transplacental carcinogen; hence, efforts should be made to reduce its consumption through foods and beverages as much as possible (Council of Europe, 1997) . The Scientific Committee on Food (SCF) of the European Union concluded in their evaluation that safrole is genotoxic and carcinogenic and that reductions in the exposure and restriction in the use levels are indicated (SCF, 2002) .
Daily intakes of safrole were estimated by the SCF to amount to 0.3 mg/day equivalent to 5 µg/kg body weight (bw)/ day for a 60 kg person (SCF, 2002) , and the Joint FAO/WHO Expert Committee on Food Additives (JEFCA) estimated the maximum dietary exposure to safrole to amount to 879 µg/ person/day equivalent to 14.6 µg/kg bw/day for a 60 kg person (JECFA, 2008) . Furthermore, a study performed amongst non-betel quid chewers in Taiwan showed that the urine of non-betel quid chewers contained 1,2-dihydroxy-4-allylbenzene, a major metabolite of safrole pointing out that intake of safrole from common spices in Taiwanese foods such as ginger and black pepper results in detectable exposure levels (Chang et al., 2002) .
The carcinogenicity of safrole has been correlated to its metabolic conversion by cytochromes P450 and sulfotransferases (SULTs) to a genotoxic metabolite, 1΄-sulfooxysafrole (Borchert et al., 1973; Ueng et al., 2005; Wislocki et al., 1977) . In humans, the first step in this bioactivation is mainly catalyzed by cytochromes P450 2A6, P450 D6*1, P450 2C9, P450 2C19, and P450 2E1 (Jeurissen et al., 2004; Liu et al., 2004; Ueng et al., 2004) . The proximate carcinogenic metabolite 1΄-hydroxysafrole can subsequently be sulfonated to the ultimate carcinogenic metabolite 1΄-sulfooxysafrole, which is unstable and spontaneously decomposes to produce an electrophilic carbonium cation forming covalent adducts with cellular macromolecules including DNA (Borchert et al., 1973; Delaforge et al., 1980; Ioannides et al., 1981; Wislocki et al., 1977) . Other metabolites of safrole are presented in Figure 1 and include products resulting from O-demethylation, epoxidation, and 3΄-hydroxylation being 1,2-dihydroxy-4-allylbenzene, 2΄,3΄-safrole oxide, and 3΄-hydroxysafrole, respectively. In rats, 1,2-dihydroxy-4-allylbenzene is the major metabolite of microsomal conversion of safrole, and this metabolite can subsequently be oxidized to an o-quinone leading to an electrophilic p-quinone methide intermediate (Bolton et al., 1994) . 2΄,3΄-Safrole oxide is susceptible to hydrolysis by microsomal epoxide hydrolase forming 2΄,3΄-dihydroxysafrole (Ioannides et al., 1981; Klungsøyr and Scheline, 1983) . 1΄-Hydroxysafrole is converted to the ultimate carcinogen by SULT-mediated conversion to 1΄-sulfooxysafrole but can also be detoxified via oxidation to 1΄-oxosafrole or glucuronidation to 1΄-hydroxysafrole glucuronide ( Fig. 1) (Punt et al., 2008) .
Species-dependent differences in bioactivation and detoxification of safrole have been reported. For example, glucuronide conjugates of 1΄-hydroxysafrole and 3΄-hydroxysafrole were detected in the urine of rats but not in that of humans (Benedetti et al., 1977) . Formation of the 1΄-oxo metabolites of the related alkenylbenzenes estragole and methyleugenol appears to be a minor detoxification pathway in rats (Al-Subeihi et al., 2011; Martati et al., 2011; Punt et al., 2008) . In humans, however, oxidation of the 1΄-hydroxy metabolite of the related alkenylbenzenes estragole and methyleugenol appeared to be a major pathway for detoxification of the 1΄-hydroxy metabolite (AlSubeihi et al., 2012; Punt et al., 2009) .
To facilitate extrapolations of high dose animal carcinogenicity data for safrole to low dose human exposure scenarios, insights are required in possible dose-dependent effects, species differences, and interindividual human variation in bioactivation and detoxification of this compound. The aim of the present study was to build a physiologically based biokinetic (PBBK) model for safrole in humans to obtain these insights.
For the model development, the kinetic parameters for the metabolic conversions of safrole and 1΄-hydroxysafrole were determined in vitro using tissue fractions of human organs that were found to be capable of metabolizing safrole or 1΄-hydroxysafrole. The outcomes of the model were compared with those of the previously defined PBBK model for safrole in rats (Martati et al., 2011) to evaluate the occurrence of species differences in bioactivation and detoxification of safrole. In addition, Monte Carlo simulations were performed to predict interindividual variation in the formation of these metabolites in the population as a whole. Finally, the outcomes of the human model were also compared with those obtained with previously defined PBBK models for the related alkenylbenzenes estragole and methyleugenol (Punt et al., 2009; Al-Subeihi et al., 2012) .
MATERIALS AND METHODS

Materials.
Pooled human liver microsomes, cytosol, and S9 were purchased from BD Gentest (Woburn, MA). Pooled human lung and kidney microsomes were obtained from BioPredic International (Rennes, France). Safrole (purity 97%), 2΄,3΄-dihydroxysafrole (purity 99%), Tris(hydroxymethyl)-aminomethane, alamethicin (from Trichoderma viride), L-ascorbic acid, uridine 5΄-diphosphoglucuronic acid (UDPGA), and 3,4-(methylenedioxy) cinnamic acid were purchased from Sigma-Aldrich (Steinheim, Germany). β-Glucuronidase and reduced β-nicotinamide adenine dinucleotide phosphate (NADPH) and oxidized (NAD + ) were obtained from Roche Diagnostics (Mannheim, Germany). Reduced glutathione (GSH) and dimethyl sulfoxide (DMSO) were purchased from Acros Organics (New Jersey). 3΄-Phosphoadenosine-5΄-phosphosulfate (PAPS) was obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands). Potassium dihydrogen phosphate, dipotassium hydrogen phosphate trihydrate, acetic acid (glacial), and magnesium chloride were purchased from VWR (Darmstadt, Germany). Chromatography grade acetonitrile was purchased from Biosolve (Valkenswaard, The Netherlands). 1΄-Hydroxysafrole was synthesized and purified as described previously (Jeurissen et al., 2004; Martati et al., 2011) . 3΄-Hydroxysafrole was synthesized from 3,4-(methylenedioxy) cinnamic acid as described previously (Angle et al., 2008 ) and purified as previously described (Martati et al., 2011) . 1΄-Oxosafrole was synthesized from 1΄-hydroxysafrole based on the method used for 1΄-oxoestragole (Wislocki et al., 1976) . 1,2-Dihydroxy-4-allylbenzene was synthesized as described previously (Bolton et al., 1994) .
Determination of the kinetic constants for microsomal conversion of safrole. Metabolites formed by microsomal conversion of safrole were identified and quantified upon incubation of safrole with human liver, lung, and kidney microsomes in the presence of NADPH. These incubations were performed as described previously for the microsomal conversion of safrole in rat tissue fractions (Martati et al., 2011) . The incubation mixtures had a final volume of 160 µl and contained 1 mg/ml microsomal protein, 3mM NADPH, and 1mM ascorbic acid in 0.2M Tris-HCl (pH 7.4). When metabolite formation was observed with a specific tissue fraction, the kinetic constants for the formation of this metabolite were determined by performing incubations for 10 min at 37°C at substrate concentrations that ranged from 10 to 1000 µM (final concentration). The reactions were started after 1 min of preincubation by addition of the substrate and terminated by addition of 40 µl of cold acetonitrile. An incubation mixture without NADPH was used as the blank.
Determination of kinetic constants for glucuronidation, sulfation, and oxidation of 1'-hydroxysafrole. To determine the kinetic constants for the metabolic conversion of 1΄-hydroxysafrole to 1΄-hydroxysafrole glucuronide, 1΄-sulfooxysafrole, and 1΄-oxosafrole, incubations were performed with human liver S9 (in case of glucuronidation and sulfonation) or human liver microsomes (in case of oxidation) in the presence of the relevant cofac- tors. The choice of the tissue fractions was based on our previous work on the related alkenylbenzene estragole (Punt et al., 2008; Punt et al., 2009) in order to make the results comparable. Incubations for glucuronidation and sulfonation were, for instance, performed with S9 fractions and not with microsomes and cytosol separately to allow for direct comparison of the kinetic constants obtained for these reactions (Punt et al., 2007; Punt et al., 2008) . All the reactions were performed as described previously for the metabolic conversion of 1΄-hydroxysafrole by rat tissue fractions (Martati et al., 2011) . In case of glucuronidation, the incubation mixtures had a final volume of 200 µl and contained (final concentrations) 10mM UDPGA, 0.2 mg S9 protein/ml in 0.2M Tris-HCl (pH 7.4), and 10mM MgCl 2 . These incubation mixtures were first pretreated on ice with 0.025 mg/ml alamethicin for 15 min to obtain maximum glucuronidation activity (Fisher et al., 2000) . The reactions were carried out for 360 min at 37°C at a substrate concentration that ranged from 100 to 4000µM (final concentration). In case of sulfonation of 1΄-hydroxysafrole, the incubation mixtures had a final volume of 100 µl, containing (final concentrations) 0.2mM PAPS, 2 mg S9 protein/ml, and 10mM GSH in 0.1M potassium phosphate (pH 8.0). These incubations were carried out for 120 min at 37°C at a substrate concentration that ranged from 250 to 4000 µM (final concentration). For oxidation of 1΄-hydroxysafrole, initial incubations were performed to determine the subcellular distribution and enzyme specificity of this enzymatic reaction. These reactions were carried out for 10 min at a substrate concentration of 1000µM with incubation mixtures that had a final volume of 100 µl, containing (final concentrations) 3mM NAD + , NADH, NADP + , or NADPH, 1 mg microsomal or cytosolic protein/ ml, and 2mM GSH in 0.2M Tris-HCl (pH 7.4). Based on these incubations, the oxidation reaction of 1΄-hydroxysafrole was observed to mainly occur in incubations with microsomes and NAD + as cofactor (data not shown), and the kinetic constants were determined for this reaction only. For the determination of these kinetic constants, incubations were carried out for 10 min at 37°C at the same conditions as described above and a substrate concentration that ranged from 10 to 4000µM (final concentration).
All of the above reactions were started after preincubation at 37°C for 1 min by addition of the substrate 1΄-hydroxysafrole diluted in DMSO and terminated by addition of cold acetonitrile amounting to 25% (v/v) of the incubation volume. The final concentration of DMSO in the incubation mixtures was kept constant at 1%. Incubation mixtures without the specific cofactors were used as blanks.
Samples and data analysis. For the determination of kinetic constants for each metabolite, three replicates were always performed. All samples were centrifuged for 5 min at 16000 g, and the supernatants were frozen at −20°C until analysis by high-performance liquid chromatography (HPLC) or ultra performance liquid chromatography (UPLC). Analysis of the samples resulting from the microsomal conversion of safrole as well as the oxidation and glucuronidation of 1΄-hydroxysafrole was performed on a Waters M600 HPLC equipped with a photodiode array detector as previously described (Martati et al., 2011) . Quantification and detection of the GSH conjugate of 1΄-sulfooxysafrole were performed on a Waters UPLC equipped with a photodiode array detector system as described previously (Martati et al., 2011) . The different metabolites of safrole and 1΄-hydroxysafrole were identified and quantified on the basis of the similarity of their ultraviolet (UV) spectrum and retention time and compared with the UV spectrum and retention time of synthesized or commercially available reference compounds as described previously (Martati et al., 2011) . In the microsomal incubations, safrole 2΄,3΄-oxide was not detected because of its swift hydrolysis by microsomal epoxide hydrolase to 2΄,3΄-dihydroxysafrole (Guenthner and Luo, 2001; Luo et al., 1992; Stillwell et al., 1974) .
The safrole concentration-dependent rate of formation of different products of microsomal conversion of safrole, and the 1΄-hydroxysafrole concentrationdependent rate of glucuronidation, oxidation, and sulfation were fitted to the standard Michaelis-Menten equation:
. In this equation, [S] represents the substrate concentration of the respective reaction. The apparent maximum velocity (V max(app) ) and apparent Michaelis-Menten constant (K m(app) ) were determined using GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA). The values of V max and K m were reported in nmol/min/ mg microsomal or S9 protein and µM, respectively. Scaling of in vitro data, expressed as nmol/min/mg protein, to in vivo data, expressed as μmol/h/g tissue, was performed as described below.
Definition of the PBBK model for safrole metabolism. A PBBK model describing the dose-dependent kinetic behavior of safrole and the formation of its metabolites in humans was developed based on the model previously defined for safrole in male rats (Martati et al., 2011) , and for the related alkenylbenzene estragole in rats (Punt et al., 2008) and in humans (Punt et al., 2009) . Figure 2 presents a schematic overview of the PBBK model used to simulate the metabolism and distribution of safrole in humans. The following compartments were included in the model: (1) liver and kidney as metabolizing compartments and (2) lung, fat, blood, richly perfused tissue, and slowly perfused tissue as separate compartments. No parallel model describing the distribution of 1΄-hydroxysafrole over the body was included because a near quantitative intrahepatic conversion of 1΄-hydroxysafrole was assumed. This assumption was based on the findings (see Results section) that the overall catalytic efficiency for the reactions converting 1΄-hydroxysafrole was higher than the catalytic efficiency for the formation of 1΄-hydroxysafrole.
The uptake of safrole from the gastrointestinal tract was assumed to follow first-order kinetics, assuming safrole to be absorbed directly to the liver with an estimated absorption constant set at 1.0 h −1 . This assumption was based on the fact that uptake of the related alkenylbenzene estragole from the gastrointestinal tract is known to be rapid and complete with an estimated absorption half-life of 0.7 h (Anthony et al., 1987; Punt et al., 2008) . 3΄-Hydroxysafrole formation was modeled in the liver and kidney. Microsomal metabolism of safrole resulting in 1΄-hydroxysafrole, 2΄,3΄-dihydroxysafrole (derived from safrole 2΄,3΄-oxide), and 1,2-dihydroxy-4-allylbenzene was only observed in the liver and therefore modeled only in the liver compartment. Formation of 1΄-hydroxysafrole in the liver was followed by its further conversion to 1΄-hydroxysafrole glucuronide, 1΄-sulfooxysafrole, and 1΄-oxosafrole. The mass balance equations in the PBBK model for time-dependent changes of safrole in the liver and kidney were essentially the same as previously described for the rat PBBK model (Martati et al., 2011) .
The urinary excretion of safrole metabolites was considered rapid and complete based on the literature data of Benedetti et al. (1977) indicating that 14 Csafrole administered to humans was excreted almost completely in the urine within 5 days and that only a limited percentage of the dose (< 2.25%) was found in feces. Based on this consideration, the transport of metabolites from liver to the kidney and urine was not included in the model. Instead, the metabolites 2΄,3΄-dihydroxysafrole, 1,2-dihydroxy-4-allylbenzene, 1΄-hydroxysafrole glucuronide, and 1΄-oxosafrole formed in liver and 3΄-hydroxysafrole formed in the liver and kidney were assumed to be all completely excreted in the urine.
The kinetic parameters for the product formation by microsomal conversion of safrole and for the glucuronidation, oxidation, and sulfation of 1΄-hydroxysafrole were determined in vitro. The V max values for the formation of microsomal safrole metabolites and of conjugated metabolites obtained from incubations with microsomal liver samples were scaled to the liver using a microsomal protein yield of 32 mg/g liver (Barter et al., 2007) . The V max values for the formation of metabolites formed in the kidney were scaled using a microsomal protein yield of 7 mg/g kidney (Beierschmitt and Weiner, 1986; Medinsky et al., 1994; Punt et al., 2008) . The V max values for the sulfation and glucuronidation of 1΄-hydroxysafrole were scaled to the liver using an S9 protein yield of 143 mg/g liver (Medinsky et al., 1994; Punt et al., 2008 , AlSubeihi et al., 2012 .
The physiological parameter values including organ volumes, cardiac output, and blood flows were taken from literature (Brown et al., 1997) and are shown in Table 1 . Partition coefficients for safrole and 1΄-hydroxysafrole were estimated from the ClogP values (DeJongh et al., 1997) . ClogP values were calculated with ChemBio3D Ultra 2010 (CambridgeSoft, MA) and were 3.18 and 1.62 for safrole and 1΄-hydroxysafrole, respectively. Mass balance and differential equations of safrole metabolism were coded and simulated with Berkeley Madonna 8.3.14 (Macey and Oster, UC Berkeley, CA) using the Rosenbrock's algorithm for stiff system. PBBK model predictions of the 304 MARTATI ET AL.
dose-dependent formation of the various products of microsomal conversion of safrole and of the various conversion products of 1΄-hydroxysafrole were performed over 120 h. In our PBBK model predictions, 120 h was selected because for this time point, in vivo human experimental data that could be used for model evaluation were available (Benedetti et al., 1977) .
Sensitivity analysis. Sensitivity analysis was used to identify the parameters that have the greatest impact on a specified model output (DeWoskin, 2007) . Normalized sensitivity coefficients (SC) were determined according to the following equation: SC = (C΄−C)/(P΄−P)*(P/C), where C is the initial value of the model output, C΄ is the modified value of the model output resulting from an increase in parameter value, P is the initial parameter value, and P΄ is the modified parameter . The effect of a 5% change in each parameter on the formation of 1΄-hydroxysafrole and 1΄-sulfooxysafrole (expressed as percentage of dose over 120 h) was analyzed. The final coefficients were calculated using Excel (Excel 2007, Microsoft Corporation, WA).
Evaluation of interindividual variability on population level using Monte Carlo simulation. To predict the influence of interindividual variability on the model outcomes, a Monte Carlo simulation was performed. For this simulation, a total number of 10,000 simulations were run. The parameters that significantly affect the outcomes as indicated by the normalized SC values higher than |0.1| were included in the Monte Carlo simulations. For these simulations, the mean μ w and standard deviation σ w describing the log-normal distribution of each parameter were derived from the mean μ x and coefficient of variation of the non-ln-transformed data using the following equation (Zhang et al., 2007) :
Meanwhile, the values of the parameters that have normalized SC values lower than |0.1| were kept at their mean values. The coefficients of variation (CVs) of the distribution of the yield of S9 protein (S9PL), microsomal protein yield of the liver (MPL), and volume of the liver (VL) were collected from the literature and corresponded to 46% (Barter et al., 2007) , 46% (Barter et al., 2007) , and 5% (EPA, 2000) , respectively. For the kinetic constants of the different metabolic reactions included in the Monte Carlo simulations, general CVs of 30% were used to represent a moderate level of uncertainty and variability (Covington et al., 2007) . The outputs were then analyzed statistically to calculate the different percentiles of the distribution of the model outcomes using GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA).
Comparison of PBBK model-based predictions for safrole with the PBBK model-based predictions for the related alkenylbenzenes estragole and methyleugenol. The PBBK model-based predictions obtained for safrole were compared with those obtained with previously developed PBBK models for the related alkenylbenzenes estragole and methyleugenol (Al-Subeihi et al., 2012; Punt et al., 2009) . To this end, the three PBBK models were run to obtain the dose-dependent formation of the respective 1΄-hydroxy metabolites, 1΄-hydroxy glucuronide metabolites, 1΄-oxo metabolites, and 1΄-sulfooxy metabolites. The PBBK models were run from dose levels of 10 −6 mg/kg bw to 100 mg/kg bw for 120 h. The lowest dose level of 10 −6 mg/kg bw was chosen to ascertain that the modeling would include realistic human dietary intake levels, and the high dose level of 100 mg/kg bw was chosen to make sure the evaluation would include dose levels known to cause tumors in in vivo rodent studies.
RESULTS
Microsomal Conversion of Safrole
HPLC analysis of incubations with pooled human liver, kidney, and lung microsomes in the presence of safrole as substrate and NADPH as cofactor reveals that conversion of safrole only occurs in incubations with pooled human liver and kidney microsomes, whereas no conversion of safrole occurs in incubations with human lung microsomes (data not shown). The metabolites formed in incubations with human liver microsomes are the same as those previously shown to be formed in incubations with rat liver microsomes (Martati et al., 2011) . Incubations of safrole with human kidney microsomes revealed the formation of only 3΄-hydroxysafrole (chromatogram not shown). Altogether the data indicate that extrahepatic microsomal conversion of safrole contributes to a minor extent to the overall microsomal conversion of safrole. Figure 3A shows the rate of formation of 2΄,3΄-dihydroxysafrole, 1΄-hydroxysafrole, 3΄-hydroxysafrole, and 1,2-dihydroxy-4-allylbenzene in incubations with pooled human liver microsomes and increasing concentrations of safrole from 10 Brown et al. (1997) .
Kinetics of Microsomal Conversion of Safrole
b DeJongh et al. (1997) .
FIG. 2.
Schematic presentation of the physiologically based biokinetic (PBBK) model used to simulate the bioactivation and detoxification of safrole in humans.
PBBK MODELING OF SAFROLE BIOACTIVATION AND DETOXIFICATION IN HUMANS
to 1000µM. Similar experiments were performed with kidney microsomes using substrate concentrations ranging from 250 to 4000µM (Fig. 3B) . Table 2 presents the apparent K m and V max values obtained from these plots and the catalytic efficiencies (V max /K m ) derived from them.
The results obtained reveal that with pooled human liver microsomes, 1,2-dihydroxy-4-allylbenzene is the major metabolite formed, followed by 1΄-hydroxysafrole, 2΄,3΄-dihydroxysafrole, and 3΄-hydroxysafrole. The catalytic efficiencies of the major metabolites 1,2-dihydroxy-4-allylbenzene and 1΄-hydroxysafrole were 4.9 and 4.3 µl/min/mg microsomal protein, respectively.
The results obtained with human kidney microsomes reveal that only 3΄-hydroxysafrole is formed. The apparent V max , K m , and catalytic efficiency calculated as the apparent V max /K m for the formation of 3΄-hydroxysafrole were 0.03 nmol/min/mg microsomal protein, 1054µM, and 0.03 µl/min/mg microsomal protein, respectively (Fig. 3B) . In the kidney, 3΄-hydroxysafrole was also formed in the blank incubations without NADPH. Correcting the amount of 3΄-hydroxysafrole formed in the complete incubation for the amount of 3΄-hydroxysafrole formed in the blank incubation contributed to the relatively large experimental variation in the K m value, revealing a coefficient variation of 80%.
Glucuronidation of 1΄-Hydroxysafrole
Formation of the glucuronosyl conjugate of 1΄-hydroxysafrole was analyzed in incubations with pooled human liver S9 and UDPGA as cofactor. Formation of the glucuronosyl conjugate of 1΄-hydroxysafrole eluting at a retention time of 24 min was observed (chromatogram not shown). This metabolite was previously identified as 1΄-hydroxysafrole glucuronide by liquid chromatography-mass spectrometry (LC-MS) (Martati et al., 2011) . Treatment of the sample with β-glucuronidase resulted in complete elimination of this metabolite and a concomitant increase in the intensity of the peak of 1΄-hydroxysafrole, corroborating that the metabolite formed corresponds to the glucuronosyl conjugate of 1΄-hydroxysafrole. Figure 4A shows the rate of glucuronidation of 1΄-hydroxysafrole with a substrate concentration increasing from 100 to 4000µM. The apparent V max and K m values derived from these data amounted to 0.1 nmol/min/mg S9 protein and 1322 µM, respectively, resulting in an apparent catalytic efficiency (V max /K m ) of 0.08 µl/min/mg S9 protein ( Table 2) .
Oxidation of 1΄-Hydroxysafrole
Formation of the glutathione adduct with 1'-oxosafrole (GS-1'-oxosafrole) was analyzed in incubations with pooled human liver microsomes, NAD + as cofactor, and GSH as a trapping agent for the 1΄-oxosafrole formed. Formation of a single metabolite with a retention time of 12 min was observed (chromatogram not shown). This metabolite was previously identified by LC-MS as GS-1'-oxosafrole (Martati et al., 2011) . Figure 4B shows the rate of oxidation of 1΄-hydroxysafrole with increasing substrate concentrations ranging from 10 to 4000µM. The apparent V max obtained from this graph amounted to 7.5 nmol/min/mg microsomal protein and the apparent K m value to 549µM, resulting in an apparent catalytic efficiency (V max /K m ) of 13.7 µl/min/mg microsomal protein ( Table 2) .
Sulfation of 1΄-Hydroxysafrole
Formation of the glutathione adduct with 1'-sulfooxysfrole (GS-1'-sulfooxysafrole) was analyzed in incubations with human liver S9 using PAPS as cofactor and GSH as trapping agent for the reactive carbocation derived from the unstable 1΄-sulfooxysafrole metabolite. A single metabolite was formed, which eluted at a retention time of 1.2 min (chromatogram not shown). This metabolite was previously identified as GS-1΄-sulfooxysafrole by LC-MS (Martati et al., 2011) . UPLC analysis of incubations of 1΄-sulfooxysafrole in the absence of GSH and in the presence of S9 protein and PAPS revealed no peak formation at 1.2 min (chromatograms not shown). Figure 4C shows the rate of formation of GS-1΄-sulfooxysafrole with a substrate concentration increasing from 250 to 4000 µM. Based on these data, the K m for the formation of 1΄-sulfooxysafrole by human liver S9 protein was determined to be 3828µM and the V max to be 0.017 nmol/min/mg S9 protein, resulting in a catalytic efficiency (V max /K m ) of 0.004 µl/ min/mg S9 protein ( Table 2) .
Comparison of Kinetic Data for Safrole Bioactivation and
Detoxification by Humans and Male Rats Table 3 presents a summary of the kinetic parameters for safrole bioactivation and detoxification by human tissue fractions compared with the kinetic parameters previously reported for male rat tissue fractions (Martati et al., 2011) . The V max values expressed as µmol/h/g tissue were obtained by scaling the in vitro V max values to V max values expressed per g liver using microsomal or S9 protein yields from the different organs that were obtained from literature (Medinsky et al., 1994) . This conversion allowed comparison of the kinetic constants obtained with different tissue fractions.
In the human liver, the scaled V max for the formation of 1΄-hydroxysafrole is about 2.5-fold lower than that for rat liver, whereas the apparent K m is 14-fold lower than that for rat liver. Overall, the catalytic efficiency (scaled V max /K m ) for the formation of the proximate carcinogenic metabolite 1΄-hydroxysafrole in human liver is five times higher than that in rat liver. The catalytic efficiency for the formation 1,2-dihydroxy-4-allyl-benzene is 1.3-fold lower in human than in male rat liver. The catalytic efficiency for the formation of 2΄,3΄-dihydroxysafrole in human liver is twofold higher than that in rat liver. The catalytic efficiencies for the formation of 3΄-hydroxysafrole are similar for human and male rat liver.
Comparison of the catalytic efficiency for glucuronidation of 1΄-hydroxysafrole by human and male rat liver reveals that this conversion is more than 3200 times less efficient in human liver, which is due to a 250-fold lower scaled V max and a 13-fold higher K m for glucuronidation in human liver. Comparison of oxidation of 1΄-hydroxysafrole in human liver with that in male rat liver reveals that this metabolic pathway is four times more efficient in human liver due to a 1.3-fold higher scaled V max value and a 3.3-fold lower K m value for 1΄-hydroxysafrole oxidation in human liver compared with rat liver. The catalytic efficiency for the formation of 1΄-sulfooxysafrole was 50-fold lower in human liver than in rat liver due to a 2-fold lower V max value and a 30-fold higher K m value.
Sensitivity Analysis of the PBBK Model Developed
To identify the key parameters that affect the levels of the proximate carcinogenic metabolite 1΄-hydroxysafrole and the ultimate carcinogenic metabolite 1΄-sulfooxysafrole, a sensitivity analysis was performed. Normalized SC values were calculated at a dose 0.005 mg/kg bw, and only parameters that had a normalized SC higher than 0.1 (in absolute value) are presented (Fig. 5) . Formation of 1΄-hydroxysafrole is predicted to be mostly affected by the kinetic constants for its formation from safrole (V max,L_1΄HS and K m,L_1΄HS ), the kinetic constants for formation for 2΄,3΄-dihydroxysafrole (V max,L_DHS and K m,L_DHS ), the kinetic constants for formation of 1,2-dihydroxy-4-allylbenzene (V max,L_DHAB and K m,L_DHAB ), MPL, and VL. The predicted formation of 1΄-sulfooxysafrole was mostly affected by the kinetic constants for formation of 1΄-hydroxysafrole (V max,L_1΄HS and K m,L_1΄HS ), for oxidation of 1΄-hydroxysafrole (V max,L_1΄HOS and K m,L_1΄HOS ), and for sulfation of 1΄-hydroxysafrole (V max,L_1΄HSS and K m,L_1΄HSS ) and to a minor extent by the kinetic constants for formation of 1,2-dihydroxy-4-allylbenzene (V max,L_DHAB and K m,L_DHAB ), for formation of 2΄,3΄-dihydroxysafrole (V max,L_DHS and K m,L_DHS ), S9PL, MPL, and VL.
Based on the sensitivity analysis, probability distributions were assigned to the model parameters to which the model outcome is most sensitive, thereby allowing to perform Monte Carlo simulations to see the effect of uncertainty and variability on the PBBK-based predictions for the total amount of metabolites excreted in the urine, for the formation of microsomal metabolites of safrole (2΄,3΄-dihydroxysafrole, 1΄-hydroxysafrole, 3΄-hydroxysafrole, and 1,2-dihydroxy-4-allylbenzene), for the conversion of 1'-hydroxysafrole (1΄-hydroxysafrole glucuronide, 1΄-oxosafrole, and 1΄-sulfooxysafrole), for concentration of safrole in liver and blood and for the concentration of 1΄-hydroxysafrole in the liver, and the predicted formation of 1΄-sulfooxysafrole at different oral doses.
Model Simulation of Total Metabolites Formed
Performance of the PBBK model thus obtained was evaluated by comparison of the PBBK model-based prediction for the total formation of metabolites that will be excreted in the urine with the reported total urinary excretion of safrole metabolites expressed as a percentage of the dose reported in the literature for humans exposed to dose levels of safrole of 0.163 and 1.655 mg/subject given orally (corresponding to 0.0027 mg/kg bw and 0.0276 mg/ kg bw for a 60 kg person) (Benedetti et al., 1977) . The metabolites to be excreted were calculated as the sum of 2΄,3΄-dihydroxysafrole, 1,2-dihydroxy-4-allylbenzene, 1΄-hydroxysafrole glucuronide, and 1΄-oxosafrole formed in liver and 3΄-hydroxysafrole formed in the liver and kidney.
The results of the Monte Carlo simulations show that at a dose of 0.163 mg/subject (Fig. 6A ), the PBBK model-predicted percentage of the dose excreted as metabolites and the actual percentage of the dose excreted in human experiments are comparable. The simulation shows that at 6 h upon oral administration of 0.163 mg/subject, the 5th, median, and 95th percentile of the predicted percentage of the dose excreted as safrole metabolites were 37, 59, and 78% of the dose, respectively, whereas the experimental value reported in the literature amounted to 55 ± 15.6% (Benedetti et al., 1977) . Upon 12 h of exposure, the reported value is 86 ± 1.3% of the dose, and the predicted percentage of 5th, median, and 95th percentile were 46, 68 and 84% of the dose, respectively.
At a dose of 1.655 mg/subject (Fig. 6B) , upon 6 h of exposure, the percentage of the dose excreted as safrole metabolites is reported to be 70% (standard deviation not given) (Benedetti et al., 1977) , whereas the predicted values of the simulation were 37, 59, and 77% of the dose for the 5th, median, and 95th percentile, respectively.
Model Simulation of the Concentration of Safrole in the Liver and Blood and the Concentration of 1΄-Hydroxysafrole in the Liver
In a next step, the PBBK model was used to make predictions for the time-and dose-dependent bioactivation and detoxification of safrole in humans. Figure 7 presents the time -FIG. 4 . 1΄-Hydroxysafrole concentration-dependent rate of the formation of (A) 1΄-hydroxysafrole glucuronide with pooled human liver S9 in the presence of UDPGA as a cofactor, (B) GS-1΄-oxosafrole with pooled human liver microsomes in the presence of NAD + as a cofactor and GSH as a trapping agent, and (C) GS-1΄-sulfooxysafrole with pooled human liver S9 homogenates in the presence of PAPS as a cofactor and GSH as a trapping agent. In the plot, each point represents the mean (± SD) of three replicates.
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MARTATI ET AL. dependent predictions for the concentration of safrole in human blood and liver and the concentration of 1΄-hydroxysafrole in human liver upon oral exposure to 0.005 mg safrole/kg bw, which is the estimated dietary human intake reported by the SCF (2002) . At a dose of 0.005 mg/kg bw, the maximum liver concentrations of safrole and 1΄-hydroxysafrole were predicted to be achieved within less than 0.5 h upon dosing. Although safrole and 1΄-hydroxysafrole concentrations in the liver are low after 12 h, full conversion is not yet reached at this time point. Only after 120 h, a more complete conversion is achieved, with 88% of the dose being metabolized to the different microsomal metabolites of safrole and almost full conversion of the 1΄-hydroxysafrole formed. The PBBK model-predicted levels of the different safrole metabolites formed after 120 h are displayed in Table 4 . The major metabolites are 1,2-dihydroxy-4-allylbenzene and 1΄-hydroxysafrole, which are predicted to amount to ~38 and ~36% of the dose, respectively. 1΄-Hydroxysafrole was mostly converted to 1΄-oxosafrole at a dose 0.005 mg/kg bw (10.8 nmol/kg bw, corresponding to 35% of the dose and to 98% of the 1΄-hydroxysafrole formed), whereas formation of the ultimate carcinogenic metabolite 1΄-sulfooxysafrole was predicted to amount to 0.04% of the dose and to 0.1% of the amount of 1΄-hydroxysafrole formed. Formation of 1΄-hydroxysafrole glucuronide was predicted to amount to 0.8% of the dose and to 2.0% of the amount of 1΄-hydroxysafrole formed.
The PBBK model-based predictions for the percentage of safrole metabolized to the various microsomal metabolites at increasing oral doses of safrole are presented in Figure 8 . At a dose of 0.005 mg/kg bw, the percentage of safrole metabolized to 2΄,3΄-dihydroxysafrole, 1΄-hydroxy-safrole, 3΄-hydroxysafrole, and 1,2-dihydroxy-4-allylbenzene was, respectively, 11, 36, 3, and 38% of the dose. When the dose was increased to e Catalytic efficiency (scaled V max /K m ).
FIG. 5.
Sensitivity analysis showing the sensitivity of the predicted formation of 1΄-hydroxysafrole (white bars) and 1΄-sulfooxysafrole (black bars) to different model parameters. VL = volume of the liver, S9PL = liver S9 protein yield, MPL = microsomal protein yield of the liver, and V max and K m are the maximum rate and the Michaelis-Menten constant for the formation of the different metabolites in the liver, respectively, 2΄,3΄-dihydroxysafrole (DHS), 1΄-hydroxysafrole (1΄HS), 1,2-dihydroxy-4-allylbenzene (DHAB), 1΄-oxosafrole (1΄HOS), and 1΄-sulfooxysafrole (1΄HSS).
PBBK MODELING OF SAFROLE BIOACTIVATION AND DETOXIFICATION IN HUMANS
100 mg/kg bw, approximately 8, 21, 4, and 39% of the dose was predicted to be metabolized to 2΄,3΄-dihydroxysafrole, 1΄-hydroxysafrole, 3΄-hydroxysafrole, and 1,2-dihydroxy-4-allylbenzene, respectively. These results reveal that 1,2-dihydroxy-4-allylbenzene is the major metabolite at low but also at high dose levels. When the dose increases, the relative formation of 2΄,3΄-dihydroxysafrole and 1΄-hydroxysafrole decreased only to a limited extent from 11 and 36% of the dose at 0.005 mg/ kg bw to approximately 8 and 21% of the dose at 100 mg/ kg bw, whereas the percentage formation of 1,2-dihydroxy-4-allylbenzene and 3΄-hydroxysafrole tended to increase to a limited extent from values amounting to, respectively, 38 and 3% of the dose at 0.005 mg/kg bw to values of 39 and 4% of the dose at 100 mg/kg bw/day. Overall, the results reveal that for safrole a dose-dependent shift in microsomal conversion of safrole, leading to a relative increase in bioactivation at higher dose levels, is not observed. This can be explained by the fact that for microsomal conversion of safrole, no saturation of an important metabolic route occurs in a dose range from 0.005 to 100 mg/kg bw/day.
Model Simulations of the Formation of Different Metabolites of Safrole and 1΄-Hydroxysafrole and Comparison of Those Metabolites Between Humans and Male Rats
To obtain insight in possible species differences in metabolic activation and detoxification of safrole between humans and male rats, the results obtained with the PBBK model for safrole in humans were compared with those obtained by the previously defined PBBK model for safrole in male rats (Martati et al., 2011) . First, a comparison is made with respect to the possible species differences in the formation of various microsomal metabolites of safrole and in the formation of 1΄-hydroxysafrole metabolites. This comparison was made at a dose level of 0.005 mg/kg bw, which is a dose level reflecting realistic daily human intakes. The second comparison focuses on the formation of 1΄-sulfooxysafrole in human and male rat liver at dose levels varying from high doses representing dose levels causing liver tumors in long-term rodent bioassays, down to dose levels reflecting realistic human exposure.
Results from a Monte Carlo simulation of the formation of microsomal metabolites of safrole and of the conversion of 1΄-hydroxysafrole and comparison of those metabolites between humans and rats are presented in Figure 9 . Differences between humans and male rats mainly occur in the formation of 1΄-hydroxysafrole and 1,2-dihydroxy-4-allylbenzene (Fig. 9A) with the median formation of 1΄-hydroxysafrole being fourfold higher in humans and the median formation 1,2-dihydroxy-4-allylbenzene being twofold lower in humans. The median formation of 2΄,3΄-dihydroxysafrole is 1.3-fold higher in humans than in male rats. The median formation of 3΄-hydroxysafrole is twofold lower in humans than in male rats (Fig. 9A) . In humans, 1΄-hydroxysafrole is mostly oxidized to 1΄-oxosafrole (Fig. 9B) , which is due to the relatively high efficiency for oxidation of 1΄-hydroxysafrole in comparison with glucuronidation and sulfonation. Predicted formation of 1΄-oxosafrole in humans is 98% of the 1΄-hydroxysafrole formed, whereas in rats this metabolite only accounts for 0.3% of the 1΄-hydroxysafrole formed (Martati et al., 2011) . In male rats, 1΄-hydroxysafrole is mostly converted to 1΄-hydroxysafrole glucuronide corresponding to 99.5% of the 1΄-hydroxysafrole formed (Martati et al., 2011) , a value that is predicted to amount to only 2% in human liver. Formation of the ultimate carcinogen 1΄-sulfooxysafrole in humans was predicted to range between 0.128% (95th percentile) and 0.01% (5th percentile) of the dose, with the median being fivefold higher in human than in rat liver (Fig. 9B) .
To see the possible dose-dependent changes in the formation of 1΄-sulfooxysafrole in different species, the dosedependent predicted formation of 1΄-sulfooxysafrole in humans was compared with that predicted for rats. The predicted formation of 1΄-sulfooxysafrole from a dose as low as 10 −6 mg/kg (Benedetti et al., 1977) at oral dose levels of (A) 0.163 mg/subject (corresponding to 0.0027 mg/kg bw for a 60 kg person) and (B) 1.655 mg/subject (corresponding to 0.0276 mg/kg bw for a 60 kg person in the PBBK model). The solid line corresponds to the predicted median value and the dashed lines to the 5th and 95th percentiles. Note that for several reported data points, the standard deviation is so small that they are not visible.
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bw to a dose as high as 100 mg/kg bw is presented in Figure 10 . From these results, it can be derived that the formation of 1΄-sulfooxysafrole in human and rat liver is predicted to be linear up to doses as high as the benchmark dose (BMD 10 ) that gives 10% extra cancer incidence (Filipsson et al., 2003) amounting to 5-39 mg/kg bw (calculated based on data from Boberg et al., 1983 and Miller et al., 1983) , when plotted on a log-log scale (Fig. 10) as well as on a linear scale (data not shown). Over the whole dose range, the median formation of 1΄-sulfooxysafrole is three-to fivefold higher in human than in rat liver, with the 5th percentile being equal to the formation of 1΄-sulfooxysafrole in rat liver and the 95th percentile being 12-to 19-fold higher.
Comparison of PBBK Model-Based Predictions for Safrole With the PBBK Model-Based Predictions for the Related Alkenylbenzenes Estragole and Methyleugenol in Humans
With the present PBBK model for safrole and the PBBK models for the related alkenylbenzenes estragole and methyleugenol previously developed (Al-Subeihi et al., 2012;  Punt et al., 2009) , comparisons can be made for the dosedependent formation of the proximate carcinogenic 1΄-hydroxy metabolites and also of the 1΄-hydroxy glucuronide, 1΄-oxo, and 1΄-sulfooxy metabolites. Figure 11 presents the formation of these metabolites for the three alkenylbenzenes as predicted by the respective human PBBK models. Figure 11A shows that the predicted formation of 1΄-hydroxysafrole is 12-fold lower than formation of 1΄-hydroxyestragole and fivefold higher than formation of 1΄-hydroxymethyleugenol. Figure 11B shows that the predicted formation of 1΄-hydroxy glucuronide is very similar for the three alkenylbenzenes. Figure 11C shows that the predicted formation of 1΄-oxosafrole is approximately twofold lower than formation of 1΄-oxoestragole and 10-fold higher than formation of 1΄-hydroxymethyleugenol. Figure 11D reveals that the formation of the unstable reactive 1΄-sulfooxy metabolite in the human liver is predicted to vary less than fivefold for the three alkenylbenzenes, being highest for estragole. The data obtained also reveal that for all three alkenylbenzenes, the formation of the ultimate carcinogenic 1΄-sulfooxy metabolite increases linearly with the dose up to dose levels of at least 10 mg/kg bw and that the overall conversion of safrole is slower than that of estragole and methyleugenol taking about 120 h instead of 24 h for full conversion.
DISCUSSION
In the present study, a PBBK model was developed to provide possibilities for the evaluation of the relative extent of bioactivation and detoxification of safrole in humans at dose levels relevant for human dietary intake.
The performance of the developed PBBK model was evaluated by comparison of the predicted levels of urinary metabolite formation with the literature reported levels of the total safrole metabolites detected in the urine of humans exposed to two different oral doses of safrole (Benedetti et al., 1977) . The model predicted the time-dependent formation of safrole urinary metabolites reasonably well at the two dose levels of 0.0027 mg/ kg bw for a 60 kg person (corresponding to 0.163 mg/subject) and 0.0276 mg/kg bw for a 60 kg person (corresponding to 1.655 mg/subject). The PBBK model-based prediction for the formation of safrole urinary metabolites at these dose levels amounted to 88% of the dose, whereas the percentage experimentally reported amounted to 97 and 96% of the dose, respectively. Based on results of a Monte Carlo simulation, the differences observed were found to be partly due to uncertainty and variability in rates of formation of different metabolites and/or in   FIG. 9 . PBBK model and Monte Carlo simulation-based prediction of (A) the formation of products of microsomal conversion of safrole in humans (indicated with H) and male rat (indicated with R) liver following an oral dose of 0.005 mg/kg bw safrole and (B) the cumulative levels of metabolites formed from 1΄-hydroxysafrole in humans (indicated with H) and male rat liver (indicated with R) at this oral dose. Results of the Monte Carlo simulation obtained with the PBBK model for humans were presented as box plots. The bottom and top of the boxes represent the 25th and 75th percentiles, respectively, and the middle of the box is the 50th percentile (the median). The ends of the whis kers attached to the box represent the 5th and 95th percentiles. For the rat model, only the average predicted for the formation of different metabolites is displayed .   FIG. 10 . PBBK model-predicted dose-dependent formation of 1΄-sulfooxysafrole in the liver of human, corresponding to the median or 50th percentile (▬▬), the 5th and 95th percentiles (▬ ▬) and rat (▬ ▬). Note that the lines of the 5th percentile of 1΄-sulfooxysafrole formation in humans and the mean of those in rats overlap.
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other parameters shown in the sensitivity analysis to influence the modeling outcomes to the largest extent. Benedetti et al. (1977) revealed that treatment of the urine of humans exposed to 1.655 mg/subject with β-glucuronidase resulted in extracted safrole metabolites at levels that were lower than those obtained for the urine of a rat exposed to safrole. This correlates with the finding of the present study that the glucuronidation of 1΄-hydroxysafrole is a minor pathway in humans when compared with rats, leaving the possibility for other conversions of 1΄-hydroxysafrole in humans. Although the extent of oxidation of 1΄-hydroxysafrole to 1΄-oxosafrole could not be evaluated against human in vivo data, the present study reveals that in human liver oxidation of 1΄-hydroxysafrole is the main detoxification route of 1΄-hydroxysafrole, and this is in line with what was observed before for detoxification of 1΄-hydroxyestragole and 1΄-hydroxymethyleugenol in human liver (Al-Subeihi et al., 2012; Punt et al., 2009 ).
The PBBK model predictions revealed that the relative formation of the various metabolites of microsomal conversion of safrole as well as the formation of the different 1΄-hydroxysafrole metabolites is hardly changing at dose levels up to 100 mg/kg bw in humans (Fig. 8 ). The PBBK model for safrole previously developed for male rats revealed similar results, showing also no dose-dependent effects on the relative extent of bioactivation and detoxification (Martati et al., 2011) . The PBBK model predictions on species differences and interindividual human variation in formation of 1΄-sulfooxysafrole can be used to derive so-called chemical-specific adjustment factors (CSAF), which allow to evaluate the appropriateness of the default uncertainty factors used in risk assessment for species differences and interindividual human variation in kinetics (Meek et al., 2003) . Comparison of the median 1΄-sulfooxysafrole formation up to dose levels of 100 mg/kg bw between rats and humans revealed that species differences are moderate, amounting to only three-to fivefold. Species-dependent differences in the bioactivation of safrole to 1΄-sulfooxysafrole are thus in line with the default factor of 4 generally assumed to reflect interspecies variation in kinetics (assuming that the default factor of 10 can be divided into a factor of 4 for kinetics and 2.5 for dynamics) (IPCS, 2010) . Monte Carlo simulations were performed to evaluate the effect of uncertainty and variability on the predicted formation of 1΄-sulfooxysafrole in the   FIG. 11 . PBBK model-based prediction of the dose-dependent formation of (A) the 1΄-hydroxy metabolite, (B) the 1΄-hydroxy glucuronide metabolite, (C) the 1΄-oxo metabolite, and (D) the 1΄-sulfooxy metabolite of estragole (▬▬▬), methyleugenol (▬ ▬ ▬), and safrole (••••) in pooled human liver after 120 h. The human PBBK models used for estragole and methyleugenol were previously described (Al-Subeihi et al., 2012; Punt et al., 2009). liver. Based on these results, a CSAF for interindividual differences in kinetics can be calculated by dividing the parameter estimate at the 95th percentile by the parameter estimate at the median (IPCS, 2005) . The CSAF obtained in this way for the predicted formation of 1΄-sulfooxysafrole is 3.9. Comparison of the CSAF with the default uncertainty factor of 3.16 for human variability in biokinetics reveals that the default uncertainty factor adequately protects 95% of the population.
Different approaches worldwide exist to assess the risk of compounds that are both genotoxic and carcinogenic. Numerical estimates of the risk associated with human exposure might be derived by extrapolation of carcinogenicity data obtained in animals at high to low dose levels relevant for the human situation. Linear extrapolation is the simplest form by which such extrapolations below the available experimental data set can be performed (COC, 2004) . This approach is, however, much debated because it is not known whether linear extrapolation actually reflects the underlying biological processes. In addition, it is argued that species differences are not taken into account in this approach (EFSA, 2005) . The results of the PBBK models for rats (Martati et al., 2011) and humans obtained in the present study, however, indicate that the kinetic data do not provide a reason to argue against such a linear extrapolation from the rat tumor data to the human situation. As illustrated in Figure 10 , the dose-dependent formation of 1΄-sulfooxysafrole in the liver of rat and human is linear from doses as high as the BMD 10 down to dose levels as low as the virtual safe dose (that gives one additional cancer risk in a million upon lifetime exposure) amounting to 0.05-0.39 µg/kg bw when plotted on a log-log scale as done in Figure 10 and also when plotted on a linear scale (Figure not shown) . Because the BMD 10 appears to be located within the linear part of the curves and the rat and human curves do not differ substantially, the PBBK results of the present study support that possible nonlinear kinetics and species differences in kinetics should not be used as an argument against using a linear low-dose cancer risk extrapolation from animal data to the low-dose human situation. This illustrates that PBBK models provide a useful tool in risk assessment of food-borne chemicals when evaluating human risks.
The 1΄-hydroxy metabolites of the alkenylbenzenes safrole, methyleugenol, and estragole and their sulfate conjugates have been shown to form DNA adducts in vivo and in vitro in a dose-dependent manner. It is of interest to compare the results for the PBBK-predicted formation of the ultimate carcinogenic metabolites of the three alkenylbenzenes with their relative potency for DNA adduct formation in vitro and in vivo and even with their BMD 10 values for tumor formation. In human liver, the differences in the level of the predicted formation of the ultimate carcinogenic 1΄-sulfooxy metabolite formed from the three alkenylbenzenes were less than fourfold, the formation being highest for estragole. For rat liver, we have previously reported similar (fivefold) differences in bioactivation of the three alkenylbenzenes to their ultimate carcinogenic 1΄-sulfooxy metabolites (Martati et al., 2011) . In HepG2 cells exposed to the alkenylbenzenes, the dose-dependent formation of DNA adducts decreased in the order methyleugenol > estragole > safrole but varied at most 3.5-fold. Furthermore, the estimated calculated BMD 10 values of safrole, methyleugenol, and estragole, amount to approximately 3-29 mg/kg bw/day (calculated using BMDS software based on the data from Boberg et al. (1983) and Miller et al. (1983) ), 22-32 mg/ kg bw (Rietjens et al., 2010) , and 9-33 mg/kg bw/day (Rietjens et al., 2010) , respectively. These results together indicate that in both rats and humans the level of bioactivation of the three alkenylbenzenes is comparable, which is in line with their comparable carcinogenic potential.
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